Unjha Formulations Ltd.

View in App
11.90 -0.60 ▼-4.8%

05 June 2023, 01:30:00 PM
Volume: 465

Company Profile

View details >>
Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.unjhaformulations.com
Market Cap 5.33 Cr.
Enterprise Value(EV) 5.60 Cr. 2023-03
Financial Indicators
Earnings per share (EPS) 0.63 Trailing Twelve Months Ending 2023-03
Price-Earning Ratio (PE) 18.96 Trailing Twelve Months Ending 2023-03
Industry PE 33.43 Trailing Twelve Months Ending 2023-03
Book Value / Share 10.44 Trailing Twelve Months Ending 2023-03
Price to Book Value 1.14 Calculated using Price: 11.89
Dividend Yield 0.00 Period Ending 2022-03
No. of Shares Subscribed 0.45 Cr. 4,480,500 Shares
FaceValue 10
About Unjha Formulations Ltd.
Unjha Formulations (U-For), incorporated in 1987, is the sister concern of Urvesh Psyllium Industries Limited. U-For is the pharmaceuticals manufacturing unit, which is going to various category of formulation like tablet, capsule, oral liquids, injectables (SVP) and powder section to manufacture ayurvedic as well as allopathy products.

Unjha Formulations Ltd. Delivery

View details >>
Delivered Qty
Traded Qty

Unjha Formulations Ltd. Performance

View details >>
1 Day
-4.80%
1 Week
-10.05%
1 Month
-14.57%
3 Month
-10.86%
6 Month
+13.33%
1 Year
+19.00%
2 Year
+22.05%
5 Year
+11.21%
10 Year
+255.22%

Unjha Formulations Ltd. Fundamental Ratios

View details >>
9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 244.18 89.75 52.48 31.18 24.22 18.57 5.55 12.35
Return on Capital Employed (%) 68.66 73.70 67.61 32.15 25.41 25.57 26.80 21.13
Return on Assets (%) 3.84 4.92 8.26 8.82 6.79 7.89 8.37 2.86 7.23

Unjha Formulations Ltd. Balance Sheet

View details >>
Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03* Rs. Cr.
Shh. Funds 0 0 1 1 1 2 2 2 2 2
Non Curr. Liab. 0
Curr. Liab. 4 3 2 3 3 2 2 2 1 1
Minority Int.
Equity & Liab. 4 3 3 4 4 4 4 4 3 3
Non Curr. Assets 1 1 1 1 1 1 1 1 1 1
Curr. Assets 2 2 2 2 3 3 3 2 2 2
Misc. Exp. not W/O 0 0 0 0 0
Total Assets 4 3 3 4 4 4 4 4 3 3

Unjha Formulations Ltd. Profit and Loss

View details >>
Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. TTM
Net Sales 7 9 10 12 11 11 11 10 14 13
Other Income 0 0 0 0 0 0 0 0 0 0
Total Income 7 9 10 12 11 12 11 10 14 13
Total Expenditure -6 -9 -10 -12 -11 -11 -10 -10 -14 -13
PBIDT 0 0 0 0 0 0 1 1 1 0
Interest 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0
Taxation 0 0 0
Exceptional Items
PAT 0 0 0 0 0 0 0 0 0 0
Adjusted EPS 0 0 1 1 1 1 1 0 1 1

Unjha Formulations Ltd. Cash Flow

View details >>
Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 0 1 -1 0 0 0 0 0 -1 0
Cash Fr. Inv. 0 0 0 0 0 0 0 0 0 0
Cash Fr. Finan. 0 0 0 0 0 0 0
Net Change 0 0 0 0 0 0 0 0 -1 0
Cash & Cash Eqvt 0 1 0 0 0 0 1 1 0 0

Unjha Formulations Ltd. Shareholding Pattern

View details >>
9 Qtrs 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%)
Promoter 36.92 36.92 36.92 36.92 36.92 36.92 36.92 36.92 36.92
Public 63.08 63.08 63.08 63.08 63.08 63.08 63.08 63.08 63.08
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Unjha Formulations Ltd. Announcements

View details >>
Fri, 02 Jun 2023
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1Name of CompanyUNJHA FORMULATIONS LTD.
2CIN NO.L99999GJ1994PLC022932
3 Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) 0.00
4Highest Credit Rating during the previous FY NA
4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable
5Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the frameworkBSE


We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No



Name of the Company Secretary: JIGAR P RAY
Designation: COMPANY SECRETARY CUM COMPLIANCE OFFICER
EmailId: info@unjhaformulations.com
Name of the Chief Financial Officer: Mr Ganpat B Prajapati
Designation: CFO
EmailId: info@unjhaformulations.com

Date: 02/06/2023

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Tue, 16 May 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication
Sub :Publish Audited Financial Results for the Quarter and Year ended as on 31/03/2023 Ref: Regulation - Reg. 33 (3) of Securities And Exchange Board Of India (Listing Obligations and Disclosures Requirements) Regulations 2015
Wed, 10 May 2023
Approval Of Audited Financial Results Of The Company For Quarter Ended And Year Ended 31St March 2023 And Out Come Of Board Meeting Held On 10.05.2023
: Intimation of Board Meeting as per Regu. 33 of Securities And Exchange Board Of India (Listing Obligations and Disclosures Requirements) Regulations 2015 - SEBI(LODR)

Unjha Formulations Ltd. Technical Scans

View details >>
Fri, 02 Jun 2023
Opening at High Opening at High
Closing Below Previous Low Closing Below Previous Low
Making Lower Lows for 3 days Making Lower Lows for 3 days
Close Below Last Week Low Close Below Last Week Low
S Closing Below Previous Low for 2 Days

Unjha Formulations Ltd. Related Stocks

View details >>
  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 239,777.54 1,008.50 +0.9%
Divi's Laboratories Ltd. 93,340.08 3,468.10 -1.2%
Cipla Ltd. 77,917.34 972.45 +0.7%
Dr. Reddy's Laboratories Ltd. 76,753.53 4,613.35 +0.1%
Apollo Hospitals Enterprise Ltd. 71,422.15 4,976.80 +0.2%
Torrent Pharmaceuticals Ltd. 60,134.99 1,779.10 +0.1%
Mankind Pharma Ltd. 58,728.27 1,420.30 -3.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 28.30 1,008.50 +0.9%
Divi's Laboratories Ltd. Consolidated 2023-03 51.54 3,468.10 -1.2%
Cipla Ltd. Consolidated 2023-03 27.85 972.45 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 17.03 4,613.35 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 87.03 4,976.80 +0.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 48.23 1,779.10 +0.1%
Mankind Pharma Ltd. Standalone 2022-03 43.99 1,420.30 -3.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 4.28 1,008.50 +0.9%
Divi's Laboratories Ltd. Consolidated 2023-03 7.36 3,468.10 -1.2%
Cipla Ltd. Consolidated 2023-03 3.33 972.45 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 3.30 4,613.35 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 11.52 4,976.80 +0.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9.69 1,779.10 +0.1%
Mankind Pharma Ltd. Standalone 2022-03 5.65 1,420.30 -3.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 1,008.50 +0.9%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,468.10 -1.2%
Cipla Ltd. Consolidated 2022-03 0.04 972.45 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,613.35 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,976.80 +0.2%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,779.10 +0.1%
Mankind Pharma Ltd. Standalone 2022-03 0.14 1,420.30 -3.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,008.50 +0.9%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,468.10 -1.2%
Cipla Ltd. Consolidated 2022-03 13.10 972.45 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,613.35 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,976.80 +0.2%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,779.10 +0.1%
Mankind Pharma Ltd. Standalone 2022-03 26.72 1,420.30 -3.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,008.50 +0.9%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,468.10 -1.2%
Cipla Ltd. Consolidated 2022-03 13.10 972.45 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,613.35 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,976.80 +0.2%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,779.10 +0.1%
Mankind Pharma Ltd. Standalone 2022-03 26.72 1,420.30 -3.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,008.50 +0.9%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,468.10 -1.2%
Cipla Ltd. Consolidated 2022-03 21,763.34 972.45 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,613.35 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,976.80 +0.2%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,779.10 +0.1%
Mankind Pharma Ltd. Standalone 2022-03 7,781.56 1,420.30 -3.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,008.50 +0.9%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,468.10 -1.2%
Cipla Ltd. Consolidated 2022-03 2,559.47 972.45 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,182.50 4,613.35 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,976.80 +0.2%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,779.10 +0.1%
Mankind Pharma Ltd. Standalone 2022-03 1,452.96 1,420.30 -3.1%

Unjha Formulations Ltd. FAQ's

What is Unjha Formulations share price?
Can I buy Unjha Formulations shares now?
What is the Market Cap of Unjha Formulations?
What are the key metrics to analyse Unjha Formulations?
What is the 52 Week High and Low of Unjha Formulations?
What is the trend of Unjha Formulations share price?